Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Clin Appl Thromb Hemost ; 28: 10760296221126172, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36217728

RESUMEN

OBJECTIVES: Preeclampsia (PE) is a serious complication of pregnancy. The fibrinolytic system play crucial roles regarding placentation and evolution of PE. AIM: To study comprehensively components of the fibrinolytic system and fibrin lysability in women with PE. DESIGN AND METHODS: 117 women with PE and matched controls were included. Tissue type plasminogen activator (t-PA), plasminogen, PAI-1, plasmin inhibitor (PI), D-dimer, the fibrinolytic potential of dextran sulphate euglobulin fraction (DEF), PAI-2, polymere PAI-2, fibrin clot lysability, thrombin activatable fibrinolysis inhibitor (TAFI) and fibrinogen were assessed. RESULTS: Women with PE had significantly increased concentrations of t-PA and PAI-1, whereas the plasma concentration of PAI-2 was significantly lower compared to controls, p < 0.0001. Polymere PAI-2 was detected in both groups. DEF, TAFI and fibrinogen were not different between the groups. D-dimer was significantly increased and plasminogen/PI together with fibrin clot lysability time decreased in the PE-group, p = 0.0004 p = 0.04, p = 0.03, p < 0.0001 respectively. CONCLUSION: This study demonstrates that PE is associated with an affected t-PA/PAI-1 system, decreased PAI-2 and increased fibrin lysability. Furthermore, PAI-2 has the potential to polymerize during pregnancy.


Asunto(s)
Antifibrinolíticos , Carboxipeptidasa B2 , Preeclampsia , Trombosis , Femenino , Humanos , Embarazo , Sulfato de Dextran/farmacología , Fibrina , Fibrinógeno/farmacología , Fibrinólisis , Plasminógeno/farmacología , Inhibidor 1 de Activador Plasminogénico , Inhibidor 2 de Activador Plasminogénico/farmacología , Activador de Tejido Plasminógeno
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA